PERSONAL INFORMATION

Sergio Romeo

Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano
Via L. Mangiagalli 25, 20133 Milano, Italy
+39.02.5031.9363

Sergio.romeo@unimi.it

WORK EXPERIENCE

2000-update	Associate Professor of Medicinal Chemistry, Faculty of Pharmacy, University of Milan, Italy.
1992-2000	Research associate, Institute of Medicinal Chemistry, Faculty of Pharmacy, University of Milan, Italy
1990-1993	Visiting scientist at the School of Pharmacy, University of Wisconsin-Madison, USA

EDUCATION AND TRAINING

1988 – 1992	Ph.D. in Medicinal Chemistry, University of Milan, Italy,
1987 - 1988	Ms cum laude in Pharmacy, University of Milan, Italy
1981 - 1987	Ms cum laude in Chemistry University of Rome, Italy

Mother tongue(s): Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	C1
German	B1	B1	B1	B1	B1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user
Common European Framework of Reference for Languages

▪

© European Union, 2002-2018 | europass.cedefop.europa.eu

ADDITIONAL INFORMATION

Research Topics

Design and synthesis of new protease inhibitors (Plasmepsins, BACE-1). Design and synthesis of new antimalarial and antileishmanial compounds. Design and synthesis of peptides and nanoparticles for anticancer therapy and diagnosis.

10 Latest Publications

1. Basilico N, Parapini S, Sparatore A, et al. In vivo and in vitro activities and ADME-tox profile of a quinolizidine-modified 4-aminoquinoline: A potent anti-P. falciparum and Anti-P. vivax blood-stage antimalarial. Molecules. 2017;22(12). doi:10.3390/molecules22122102.
2. Gabriele E, Porta F, Facchetti G, Galli C, Gelain A, Meneghetti F. Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest. Arkivoc. 2017;2017(2):235-250. doi:10.3998/ark.5550190.p009.805.
3. Almirante N, Storoni L, Bastia E, Brambilla S, Romeo S. Preparation of nitric oxide donating carnosine compounds for ophthalmic use. Eur Pat Appl. 2016;(EP2993172A1):31pp.;
4. Avvakumova S, Galbiati E, Sironi L, et al. Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor. Bioconjug Chem. 2016;27(12). doi:10.1021/acs.bioconjchem.6b00568.
5. Galbiati E, Gambini L, Civitarese V, et al. “Blind” targeting in action: From phage display to breast cancer cell targeting with peptide-gold nanoconjugates. Pharmacol Res. 2016;111:155-162. doi:10.1016/j.phrs.2016.06.007.
6. Gambini L, Rizzi L, Pedretti A, et al. Picomolar inhibition of plasmepsin V, an essential malaria protease, achieved exploiting the prime region. PLoS One. 2015;10(11). doi:10.1371/journal.pone.0142509.
7. Pancotti A, Parapini S, Dell’Agli M, et al. Discovery of oxybisbenzoylamides as a new class of antimalarial agents. Med Chem Commun. 2015;6(6):1173-1177. doi:10.1039/C5MD00115C.
8. Kanodia S, Kumar G, Rizzi L, et al. Synthetic peptides derived from the C-terminal 6 kDa region of Plasmodium falciparum SERA5 inhibit the enzyme activity and malaria parasite development. Biochim Biophys Acta - Gen Subj. 2014;1840(9):2765-2775. doi:10.1016/j.bbagen.2014.04.013.
9. Menegazzi M, Mariotto S, Dal Bosco M, et al. Direct interaction of natural and synthetic catechins with signal transducer activator of transcription 1 affects both its phosphorylation and activity. FEBS J. 2014;281(3):724-738. doi:10.1111/febs.12618.
10. Bruno M, Trucchi B, Monti D, Romeo S, Kaiser M, Verotta L. Synthesis of a Potent Antimalarial Agent through Natural Products Conjugation. ChemMedChem. 2013;8(2):221-225.

Financed Projects

2015-2018 PRIN2015: “Towards multi-stage drugs to fight poverty related and neglected parasitic diseases: synthetic and natural compounds directed against Leishmania, Plasmodium and Schistosoma life stages and assessment of their mechanisms of action”

2010-1012: Local Coordinator of PRIN2008: “Antimalarial Lead Compounds from Nature: Isolation, Optimization and Biological Evaluation”

2006-2011: Partner of “Antimal” FP6: Malaria Drugs Initiative”.

Personal information

I authorize the handling of personal information in this curriculum, according to D.Lgs n. 196/03 and following modifications and Regulations EU 679/2016 (General Regulations concerning Data Protection or GRDP) and art. 7 of University Regulations concerning protection of personal information.

-
- I authorize, according to D.lgs 14/03/2013 n. 33 concerning transparency, in case of conferment of the position and of the fellowship, the publication of this curriculum in the web site of Università degli Studi di Milano in the section “Amministrazione trasparente”, “Consulenti e collaboratori”

Milano 06/11/2018

Signature